Genflow Biosciences PLC (OTC:GENFF) Financings

Genflow Biosciences PLC

Financings

RaiseDateIn US dollars
Private placement of new ordinary shares (and/or warrants)
Announced: private placement
Use of proceeds: Moving MASH program to IND-enabling stage, animal health dog trial payment and licensing, glaucoma proof of concept studies, and EU and US patent work
Feb 11, 2026
Private placement of new ordinary shares with warrants
Cancelled: £340,000 · £0.85 a share · Warrants at £1.2 for 24 months
Buyers: Eric Leire (40,000,000 new ordinary shares at 0.85 pence, to be directed to an institution for sale to a purchaser)
Insiders: Subscription by CEO and director Eric Leire, who will direct the shares to an institution for immediate sale to a purchaser
Use of proceeds: Continue the dog study while awaiting the Wallonia region grant; working capital
Oct 9, 2025US$456,978
Private placement of new ordinary shares with warrants
Closed: £440,000 raised · GBX 1.1 a share · Warrants at GBX 1.2 for 24 months
Buyers: Eric Leire (4,545,454 New Ordinary Shares); consortium of existing shareholders (35,454,546 New Ordinary Shares)
Insiders: CEO and director Eric Leire subscribed for the 40,000,000 shares, directing 35,454,546 to existing shareholders and keeping 4,545,454
Oct 9, 2025US$586,174
Private placement of new ordinary shares with warrants
Closed: £500,000 raised · GBX 0.8 a share · Warrants at GBX 1.5 for 36 months
Buyers: Eric Leire (subscription for 62,500,000 New Ordinary Shares, to be directed to an institution and sold to a purchaser)
Insiders: Subscription by CEO and director Eric Leire, who directs the shares to an institution that sells them to a purchaser at the same price
Use of proceeds: Advance a proof-of-concept trial of its therapeutic candidate in aged dogs
May 9, 2025US$665,147

Read by 6ix AI from the company's releases